Lehtiö, Janne http://orcid.org/0000-0002-8100-9562
Arslan, Taner http://orcid.org/0000-0002-2388-1811
Siavelis, Ioannis
Pan, Yanbo http://orcid.org/0000-0001-9442-7782
Socciarelli, Fabio
Berkovska, Olena http://orcid.org/0000-0002-8811-0591
Umer, Husen M.
Mermelekas, Georgios
Pirmoradian, Mohammad
Jönsson, Mats
Brunnström, Hans http://orcid.org/0000-0001-7402-138X
Brustugun, Odd Terje
Purohit, Krishna Pinganksha
Cunningham, Richard
Foroughi Asl, Hassan
Isaksson, Sofi
Arbajian, Elsa
Aine, Mattias http://orcid.org/0000-0002-0851-5952
Karlsson, Anna http://orcid.org/0000-0001-6974-5965
Kotevska, Marija
Gram Hansen, Carsten
Drageset Haakensen, Vilde
Helland, Åslaug
Tamborero, David
Johansson, Henrik J. http://orcid.org/0000-0003-4729-4205
Branca, Rui M.
Planck, Maria
Staaf, Johan http://orcid.org/0000-0001-5254-5115
Orre, Lukas M.
Funding for this research was provided by:
Vetenskapsrådet
Cancerfonden (postdoc grant)
Stiftelsen för Strategisk Forskning
Familjen Erling-Perssons Stiftelse
EC | Horizon 2020 Framework Programme (OncoBiome 825410, AIpBand 764281)
Radiumhemmets Forskningsfonder
Karolinska Institutet (KID, KID, KID)
University of Edinburgh (Chancellor’s Fellowship)
Worldwide Cancer Research
the Sjöberg Foundation
Fru Berta Kamprads Stiftelse
Lunds Universitet (BioCARE)
Stiftelsen Jubileumsklinikens Forskningsfond mot Cancer
Article History
Received: 2 October 2020
Accepted: 20 August 2021
First Online: 22 November 2021
Competing interests
: J.L. has received grant funding from AstraZeneca, Roche and Novartis (not financing this manuscript). J.L. and L.M.O. are shareholders of FenoMark Diagnostics. J.L., T.A., I.S. and L.M.O. are co-inventors on a patent application related to this work. J.L. and D.T. are associated with a Roche-financed Cancer Core Europe clinical trial (not associated with this manuscript). Since completing his contribution to the current work, M. Pirmoradian has become an employee of AstraZeneca. All other authors declare no competing interests.